
|Articles|October 3, 2012
yervoy cancernetwork header
Advertisement
<<
This resource is sponsored by Bristol-Myers Squibb and contains promotional material.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
4
How Will the Continued Success of ADCs in Breast Cancer Be Propelled in the Future?
5



![“[This approval] will be a quite dramatic change in our philosophy and practice in multiple myeloma," according to Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/3cab3ada4c023b68c118240a512e31d72a7f931b-1200x628.png?w=350&fit=crop&auto=format)















































































